Patrys Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PAB.AX research report →
Price Chart
About the company
Based in Melbourne, Australia, Patrys Limited and its subsidiaries specialize in developing and commercializing advanced antibody technologies for cancer treatment. Their leading therapeutic, Deoxymab 3E10, is a distinctive DNA damage-repair antibody capable of penetrating cell nuclei. The company's pipeline also includes PAT-DX1, an antibody fragment specifically designed to target both primary and secondary brain cancers.
- CEO
- Samantha South
- IPO
- 2007
- Employees
- 15
- HQ
- Nedlands, WA, AU
Get TickerSpark's AI analysis on PAB.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $11.24M
- P/E
- -2.77
- PEG
- 0.00
- P/S
- 114.64
- P/B
- 5.94
- EV/EBITDA
- -2.23
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -4295.26%
- Net Margin
- -4602.61%
- ROE
- -406.05%
- ROIC
- -276.54%
Latest fiscal year · YoY change
- Revenue
- $828.54K-40.6%
- Gross Profit
- $828.54K-40.6%
- Op Income
- $-2,709,553
- Net Income
- $-3,013,303+14.9%
- EPS
- $-0.00+29.4%
- OCF Growth
- +2.3%
- FCF Growth
- +2.5%
- 52W High
- $0.05
- 52W Low
- $0.03
- 50D MA
- $0.04
- 200D MA
- $0.03
- Beta
- 1.26
- RSI (14)
- 43
- Avg Volume
- 771.24K
No earnings-call transcripts are available for PAB.AX yet.
- Free Float
- 99.1%
- Shares Outstanding
- 340.73M
- Float Shares
- 337.60M
Our PAB.AX coverage
Recent articles, reports, and earnings notes.
No research on PAB.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PAB.AX report →